These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24346166)

  • 1. Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data.
    Zhang Z; Qu Y; Zhang B; Nie L; Soon G
    Stat Methods Med Res; 2016 Oct; 25(5):2103-2119. PubMed ID: 24346166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.
    Zhang Z; Ma S; Nie L; Soon G
    Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28343164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A flexible B-spline model for multiple longitudinal biomarkers and survival.
    Brown ER; Ibrahim JG; DeGruttola V
    Biometrics; 2005 Mar; 61(1):64-73. PubMed ID: 15737079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender difference in HIV-1 RNA viral loads.
    Donnelly CA; Bartley LM; Ghani AC; Le Fevre AM; Kwong GP; Cowling BJ; van Sighem AI; de Wolf F; Rode RA; Anderson RM
    HIV Med; 2005 May; 6(3):170-8. PubMed ID: 15876283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian inference on joint models of HIV dynamics for time-to-event and longitudinal data with skewness and covariate measurement errors.
    Huang Y; Dagne G; Wu L
    Stat Med; 2011 Oct; 30(24):2930-46. PubMed ID: 21805486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining biomarkers for classification with covariate adjustment.
    Kim S; Huang Y
    Stat Med; 2017 Jul; 36(15):2347-2362. PubMed ID: 28276080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study.
    Prague M; Commenges D; Gran JM; Ledergerber B; Young J; Furrer H; Thiébaut R
    Biometrics; 2017 Mar; 73(1):294-304. PubMed ID: 27461460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A constrained single-index regression for estimating interactions between a treatment and covariates.
    Park H; Petkova E; Tarpey T; Ogden RT
    Biometrics; 2021 Jun; 77(2):506-518. PubMed ID: 32573759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Covariates and Random Effects in Evaluating Predictive Biomarkers Under a Potential Outcome Framework.
    Zhang Z; Nie L; Soon G; Liu A
    Ann Appl Stat; 2014 Dec; 8(4):2336-2355. PubMed ID: 26779295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing interaction between treatment and high-dimensional covariates in randomized clinical trials.
    Callegaro A; Spiessens B; Dizier B; Montoya FU; van Houwelingen HC
    Biom J; 2017 Jul; 59(4):672-684. PubMed ID: 27763683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
    Huang Y; Pantaleo G; Tapia G; Sanchez B; Zhang L; Trondsen M; Hovden AO; Pollard R; Rockstroh J; Ökvist M; Sommerfelt MA
    EBioMedicine; 2017 Oct; 24():195-204. PubMed ID: 28970080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.
    Phillips AN; Pillay D; Miners AH; Bennett DE; Gilks CF; Lundgren JD
    Lancet; 2008 Apr; 371(9622):1443-51. PubMed ID: 18440426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
    Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
    J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine.
    Dunn G; Emsley R; Liu H; Landau S
    Clin Trials; 2013 Oct; 10(5):709-19. PubMed ID: 24000376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.